M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
Pharmasset selects PSI-879 as nucleotide analogue inhibitor of hepatitis C for preclinical development
6 October 2009 - US clinical-stage pharmaceutical company Pharmasset Inc (NASDAQ: VRUS) said today it has nominated PSI-352879 (PSI-879) as a second development candidate from two series of purine analogues for the treatment of chronic hepatitis C virus (HCV) infection.
PSI-879 is a...
If you want to view the full text of this story, you must first purchase archive retrieval credits.